Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Program BALL is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for B lymphoblastic leukemia/lymphoma. The cases presented will be a mixture of Children's Oncology Group (COG) approved B-ALL MRD method and laborotory developed assays.
- Two 1.1-mL specimens containing a cell line/whole blood mixture simulating B lymphoblastic leukemia/lymphoma minimal residual disease
- One online case consisting of gated dot plots
This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.
- Shipment A: January 18
- Shipment B: July 13